FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

The phase 3 trial compares trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) in combination with pertuzumab (Perjeta, Genentech) vs. current first-line standard of care in patients ...

CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive metastatic breast cancer.

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast ...

ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer — Impressive PFS with combination of trastuzumab deruxtecan and pertuzumab ...

Trastuzumab deruxtecan plus pertuzumab shows promising results as a potential new first-line treatment for HER2-positive breast cancer at ASCO 2025.

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...

Topline data were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki followed by THP in patients with high-risk, locally advanced HER2-positive early stage breast cancer.

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line ...